Master of Medicine - Allergic Diseases

Western Sydney University

Type of institution: University/Higher Education Institution
Level: Postgraduate
CRICOS: 00917K

The Master of Medicine (Allergic Diseases) equips medical practitioners in clinical practice with advanced theoretical knowledge and clinical expertise in allergic diseases and core epidemiological research methods. Students will build on and integrate skills through online and face to face learning activities over a three year part-time program. The program will enable students to competently diagnose and manage patients with allergic diseases, and critically appraise new concepts and evidence for clinical and research use. Students will gain the fundamental epidemiological and statistical concepts and skills required to design and conduct studies and pursue further research training in allergic diseases.

Structure

120 credit points

Subjects

  • Allergic Sciences
  • Mental Health Aspects of Allergic Diseases
  • Clinical Allergy
  • Research Protocol Design and Practice
  • Health Advancement and Health Promotion.

Standard entry requirements

Applicants must be qualified and registered medical practitioners (doctors) in current clinical practice in Australia or New Zealand. See website for more details

Further information

Students must supply a certified copy of their medical degree (MBBS, MBChB or equivalent qualification) and current medical registration, and proof of proficiency in English (if medical qualification was obtained overseas) at the time of application. In addition, students for the Graduate Diploma in Allergic Diseases (exit only) and Master of Medicine (Allergic Diseases) must be qualified and registered medical practitioners in clinical practice, and be able to access a specialist Immunology and Allergy clinic.

Related courses

Browse more courses
Is the information on this page correct? Request update
Sign up to our newsletter for the latest scholarships and education news
You must agree before submitting.

Subscribe to our newsletter

Join the conversation